WuXi Biologics Achieves Prestigious ISO 20400 Sustainable Procurement Certification

WuXi Biologics (2269.HK), the global biopharmaceutical contract research, development and manufacturing organization, has announced that it has been awarded the ISO 20400 Sustainable Procurement certification, an internationally recognized benchmark for integrating sustainability into procurement practices. This achievement highlights the company’s dedication to embedding environmental, social and governance (ESG) principles throughout its supplier lifecycle management — from due diligence and onboarding to performance monitoring and, if necessary, contract termination — ensuring compliance, transparency and responsible practices across its supply chain. Dr. Chris Chen, CEO and Chairman of WuXi Biologics’ ESG Committee, emphasized that as an active participant in the Pharmaceutical Supply Chain Initiative (PSCI), the company uses world‑class management strategies to build a resilient and sustainable value chain that meets global client needs while advancing responsible industry standards. In addition to this latest recognition, WuXi Biologics has committed to science‑based climate targets and engages with suppliers on climate action, risk mitigation, and operational efficiency to promote positive impacts across its entire value chain. #WuXiBiologics #SustainableProcurement #ISO20400 #ESGLeadership #SlimScan #GrowthStocks #CANSLIM